BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21717457)

  • 1. Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo.
    Segerström L; Baryawno N; Sveinbjörnsson B; Wickström M; Elfman L; Kogner P; Johnsen JI
    Int J Cancer; 2011 Dec; 129(12):2958-65. PubMed ID: 21717457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
    Geng X; Xie L; Xing H
    Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo.
    Johnsen JI; Segerström L; Orrego A; Elfman L; Henriksson M; Kågedal B; Eksborg S; Sveinbjörnsson B; Kogner P
    Oncogene; 2008 May; 27(20):2910-22. PubMed ID: 18026138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma.
    Guenther MK; Graab U; Fulda S
    Cancer Lett; 2013 Sep; 337(2):200-9. PubMed ID: 23684925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting aberrant PI3K/Akt activation by PI103 restores sensitivity to TRAIL-induced apoptosis in neuroblastoma.
    Opel D; Naumann I; Schneider M; Bertele D; Debatin KM; Fulda S
    Clin Cancer Res; 2011 May; 17(10):3233-47. PubMed ID: 21355080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a novel synthetic lethality of combined inhibition of hedgehog and PI3K signaling in rhabdomyosarcoma.
    Graab U; Hahn H; Fulda S
    Oncotarget; 2015 Apr; 6(11):8722-35. PubMed ID: 25749378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
    Chiarini F; Falà F; Tazzari PL; Ricci F; Astolfi A; Pession A; Pagliaro P; McCubrey JA; Martelli AM
    Cancer Res; 2009 Apr; 69(8):3520-8. PubMed ID: 19351820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma.
    Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE
    Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GD2 ganglioside specific antibody treatment downregulates PI3K/Akt/mTOR signaling network in human neuroblastoma cell lines.
    Durbas M; Horwacik I; Boratyn E; Kamycka E; Rokita H
    Int J Oncol; 2015 Sep; 47(3):1143-59. PubMed ID: 26134970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma.
    Santo EE; Stroeken P; Sluis PV; Koster J; Versteeg R; Westerhout EM
    Cancer Res; 2013 Apr; 73(7):2189-98. PubMed ID: 23378341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
    Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
    Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
    Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
    Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
    Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
    Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo.
    Wickström M; Dyberg C; Shimokawa T; Milosevic J; Baryawno N; Fuskevåg OM; Larsson R; Kogner P; Zaphiropoulos PG; Johnsen JI
    Int J Cancer; 2013 Apr; 132(7):1516-24. PubMed ID: 22949014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-tumor effects of PIM/PI3K/mTOR triple kinase inhibitor IBL-302 in neuroblastoma.
    Mohlin S; Hansson K; Radke K; Martinez S; Blanco-Apiricio C; Garcia-Ruiz C; Welinder C; Esfandyari J; O'Neill M; Pastor J; von Stedingk K; Bexell D
    EMBO Mol Med; 2019 Aug; 11(8):e10058. PubMed ID: 31310053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PI3K inhibitors prime neuroblastoma cells for chemotherapy by shifting the balance towards pro-apoptotic Bcl-2 proteins and enhanced mitochondrial apoptosis.
    Bender A; Opel D; Naumann I; Kappler R; Friedman L; von Schweinitz D; Debatin KM; Fulda S
    Oncogene; 2011 Jan; 30(4):494-503. PubMed ID: 20856197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacologic synergy between dual phosphoinositide-3-kinase and mammalian target of rapamycin inhibition and 5-fluorouracil in PIK3CA mutant gastric cancer cells.
    Bhattacharya B; Akram M; Balasubramanian I; Tam KK; Koh KX; Yee MQ; Soong R
    Cancer Biol Ther; 2012 Jan; 13(1):34-42. PubMed ID: 22336586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.
    Smith JR; Moreno L; Heaton SP; Chesler L; Pearson AD; Garrett MD
    Mol Oncol; 2016 Apr; 10(4):538-52. PubMed ID: 26686971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
    López-Fauqued M; Gil R; Grueso J; Hernandez-Losa J; Pujol A; Moliné T; Recio JA
    Int J Cancer; 2010 Apr; 126(7):1549-61. PubMed ID: 19810100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.